Core Viewpoint - China Life Insurance (02628.HK) is experiencing a strong upward trend in its stock price, currently at 17.16 HKD, reflecting a 1.06% increase, following a rebound from a short-term support level of 16.2 HKD [1] Technical Analysis - The stock price has surpassed all major technical moving averages, including the 10-day moving average at 16.4 HKD, the 30-day moving average at 15.63 HKD, and the 60-day moving average at 15.23 HKD, indicating a bullish structure [1] - The stock is approaching the first resistance level at 17.3 HKD, with a potential target of 18.3 HKD if this level is breached [2] - The recent volatility is reflected in a 6.8% fluctuation over five days, with an RSI index at 72, indicating a technical overbought condition [3] - The overall technical indicators are rated as "strong buy," with a signal strength of 16 points, supported by bullish momentum across all categories [3] - The MACD has completed a golden cross and maintains an expanding trend, supporting a continued upward pattern [3] - The price has successfully broken through the Ichimoku cloud, suggesting further upward potential in the coming weeks [3] Derivative Products Performance - On June 6, China Life's related structured products performed well, with a 2.76% increase in the underlying stock, leading to significant gains in derivatives [4] - The Societe Generale bull certificate (53998) led with a 15% increase, outperforming the underlying stock, showcasing the leverage advantage of bull certificates in rising markets [4] Investment Options - Current market conditions provide diverse investment options through China Life's related structured products, with call options offering a leverage of 4.1 times [7] - Bull certificates from HSBC (53706) and JPMorgan (53835) offer over 5 times actual leverage, with a buyback price set at 14 HKD [7] - For bearish strategies, Citigroup's bear certificate (56865) offers a leverage of 4.7 times, with a buyback price set at 20 HKD, providing a favorable risk-reward ratio [7] Summary - China Life is in a healthy upward phase with strong volume-price support and trend indicator resonance, but caution is advised due to potential overbought conditions and divergence risks [10]